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Abstract
This study aimed to determine the aerosolization behavior of a nanodispersion of budesonide, 
prepared using microfluidic reactors. The size and morphology of budesonide nanoparticles 
were characterized by photon correlation spectroscopy (PCS) and transmission electron 
microscopy (TEM). Processing/formulation parameters for formation of the nanoparticles were 
studied to determine their effects on the particle size. Results showed a narrow distribution 
for budesonide nanodispersion with spherical and smooth surfaced particles. To investigate 
the in-vitro aerosolization performance of the nanodispersion, the preparation was compared 
with a commercially available budesonide microsuspension using the Comité Européen 
Normalization (CEN) methodology. Aerosolization results showed that the fine particle 
fraction (FPF) generated from the budesonide nanodispersion was significantly higher than 
that of the marketed budesonide (ie. mean (SD) 56.88 (3.37)% vs. 38.04 (7.82)%, respectively). 
Additionally, mass median aerodynamic diameter (MMAD) of nano-budesonide dispersion was 
significantly smaller than the microsuspension (ie. mean (SD) 3.91 (0.49) vs. 6.22 (1.09) µm, 
respectively), with nebulization time of nano-budesonide dispersion significantly shorter than 
the marketed budesonide microsuspension (ie. 12.3 (0.37) vs. 14.85 (0.36) min, respectively). 
The produced nanodispersion was found to be stable over a period of 10 days if stored at 4 °C.
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Introduction
Nanosizing, or reduction of particle size down 
to the sub-micron levels (1), has been widely used 
in recent years to improve several properties of 
pharmaceuticals e.g. their bioavailability  (2, 3). 
Typically, nanosizing can be achieved through 
top-down (breaking of larger drug particles 
into smaller ones) or bottom-up (building of 
nanoparticles from molecular scale components) 
approaches. A recently popularized approach 
in bottom-up methods is precipitation using 
microfluidic reactors. Microfluidic reactors 
comprise microchannel having laminar fluids, 
meaning that adjacent streams of miscible 
fluids flow through microchannels side by 
side, with minimum turbulence (4). Fluid 
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deviation (GSD) and emitted dose must be 
addressed for any proposed preparation as 
a part of documentation process. However, 
such parameters have not been detailed for 
nanodispersions of budesoinde, especially 
in case of preparations with particles sizes < 
200nm where nanosizing shows its real effects 
such as substantial increases in solubility (16, 
17). The aim of this study was to formulate 
and evaluate a nano-budesonide formulation 
suitable for nebulization and its aerodynamic 
characteristics compared to the commercially 
available formulation. 
Experimental
Materials 
Micronized budesonide (Pharm. grade), 
polysorbate 80 and sodium chloride (Pharm 
grade) were purchased from Industriale Chimica 
s.r.l. (Italy) and Sigma-Aldrich (Germany), 
respectively. Absolute ethanol, acetonitrile 
and methanol (HPLC grade) were from Fisher 
Scientific Ltd (UK). Potassium dihydrogen 
orthophosphate and disodium hydrogen 
phosphate were purchased from VWR (UK). 
Pulmicort Respules® 1 mg/2mL was from 
AstraZeneca (UK). Distilled water was obtained 
using PurelabTM (ELGA, UK). 
Solubility study
Considering the safety concerns, to prepare 
a formulation for pharmaceutical purposes, for 
the process of budesonide nanoprecipitation, 
ethanol and water were chosen as solvent and 
antisolvent, respectively. Accordingly, solubility 
of budesonide in ethanol, water and different 
combinations of mixture of ethanol-water 
was checked. Excess amounts of budesonide 
were added to sealed vials containing ethanol, 
water or mixtures. All dispersions were shaken 
for 24 h at room temperature (25 °C). The 
dispersions were then filtered using hydrophilic 
Durapore filters (0.45 μm, Milipore, Ireland). 
To determine the amount of drug dissolved, 
UV spectroscopy was used employing V-530 
UV-Vis spectrophotometer (Jasco, Japan) at 
wavelength 240 nm. Aliquots were examined 
and the solubility of drug was identified in 
each sample. Experiments were carried out in 
mixing in such reactors results from diffusion 
of molecules across the interface between fluid 
streams (5). Such a unique laminar flow can be 
exploited to generate nano-sized drug particles 
through controlled antisolvent precipitation in 
microreactors (6-8).
Administration of marketed budesonide 
suspension (e.g. Pulmicort® Respules®) 
by nebuilization is common in pediatric 
patients and adults who show difficulties in 
coordination of breathing when using DPIs and/
or lack sufficient inspiratory capabilities (9, 
10). However, several limitations are associated 
with the use of marketed microsuspensions of 
budesonide. Unintended deposition and possible 
low bioavailability of the drug, insufficient 
interactions with respiratory surfaces, lengthy 
treatment time and problems in administration 
with faster nebulizers have been reported with 
nebulized microsuspensions (11). Moreover, 
the unwanted deposition may cause localized 
immune suppression and local side effects such 
as oral yeast infections as well as the increased 
risk of systemic absorption (12). 
Although several studies on nebulization 
of nanodispersions have been reported (13), 
works on nebulization of nanodispersions 
of budesonide are limited. Jacob and Müller 
have reported improved respirable fraction 
of budesonide prepared using high pressure 
homogenizer in a jet nebulizer with particle 
size ~ 500-600 nm (14). In a clinical study, 
similar pulmonary absorption was reported 
for nano and micro suspension with a faster 
delivery rate in nanosuspension (9). An 
in-vitro study showed the potential of a 
submicron suspension of budesonide to deliver 
substantially more fine particles compared 
with the microsuspension (15). A clinical 
study of the submicron formulation showed 
no side effect compared with the marketed 
formulation. The improved absorption and 
drug delivery rate was also reported in 
this study (12). Nevertheless, considering 
the mentioned studies, no comprehensive 
work so far has reported the aerodynamic 
behavior of the nebulized nanodispersion of 
budesonide. Parameters such as fine particle 
fraction (FPF), mass median aerodynamic 
diameter (MMAD), geometric standard 
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triplicates.
Preparation of budesonide nanodispersions
Budesonide nanodispersions (ND) were 
prepared using configured microfluidic reactors 
(Internal diameter 0.5 and 1 mm, fluid inlet angle 
10, 25 and 50°) as detailed previously (7). The 
effect of different factors possibly affecting the 
nanoprecipitation process, namely, antisolvent 
flow rate, drug concentration, internal diameter, 
and inlet angles of microreactor was also 
examined. 
The inhalation studies employed the 
budesonide nanodispersion formulation with the 
smallest particle size in Table 1 (i.e. sample No. 
5). To equalize the concentration of budesonide 
in the sample understudy and that of commercial 
suspension (i.e. Pulmicort Respules®, 0.5 mg/
mL), the following approach was used: before 
nebulization studies, the preparation was further 
diluted with a solution of sodium chloride and 
polysorbate 80 to obtain a final concentration of 
0.5 mg/mL, 0.9 %(W/V) and 0.02 %(W/V) for 
budesonide, sodium chloride and polysorbate 
80, respectively (budesonide ND).
Particle size measurement
The average particle size diameter (Z-Ave) and 
the polydispersity index (PDI) of the samples were 
determined by photon correlation spectroscopy 
(PCS) technique using Zetasizer® NanoS 
(Malvern Instruments, UK). Dispersions were 
analyzed without dilution and the mean Z-Ave and 
polydispersity index (PDI) of three measurements 
was recorded. The accuracy of the instrument was 
calibrated by a NanosphereTM size standard, 500 
nm (Duke Scientific Corporation, USA).
Measurement of zeta potential
Zeta potential of the budesonide ND was 
measured by a Zetasizer® NanoS (Malvern 
Instruments, UK). The measurement was 
performed without dilution. All measurements 
were made in triplicate and the mean values 
were reported.
Morphology of budesonide particles
The morphology of different budesonide 
particles was examined using transmission 
electron microscopy (TEM) or scanning electron 
microscopy (SEM). For budesonide ND, drops 
of the dispersion were placed on a carbon grid, 
stained with 2% uranyl acetate solution and 
transferred to the TEM (JEM-1200EX, Japan 
Electron Optics Laboratory Corporation, Japan) 
operated at 120 kV. Unprocessed budesonide 
and budesonide of the commercial suspension 
(adsorbed on carbon grid and air-dried) were 
examined by SEM (Quanta 400, FEI Company, 
Cambridge, UK) after being mounted onto a 
graphite layer on an aluminum cylinder under 
vacuum.
Sample No.
Input variables Output variable
Antisolvent flow 
rate (mL/min)
Solvent flow 
rate (mL/min)
Drug concentration in 
the solvent (mg/mL)
Internal diameter 
(mm)
Inlet angle 
(°)
Mean (SD) particle 
size (nm)
1 0.5 0.5 5 1.0 10 258 (2.3)
2 1.0 0.5 5 1.0 10 236 (7.5)
3 1.5 0.5 5 1.0 10 212 (3.3) 
4 2.0 0.5 5 1.0 10 172 (3.2)
5 2.5 0.5 5 1.0 10 160 (4.0)
6 0.5 0.5 10 1.0 10 242 (4.8)
7 0.5 0.5 15 1.0 10 231 (5.4)
8 0.5 0.5 20 1.0 10 225 (6.2)
9 0.5 0.5 5 0.5 10 225 (6.2)
10 0.5 0.5 5 0.5 25 276 (8.2)
11 0.5 0.5 5 0.5 50 303 (7.3)
Table 1. The impact of experimental conditions and microreactor set up on budesonide mean particles size (n=3).
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Aerosolization
Aerosol output rate
The aerosol output of the tested preparations 
(budesonide ND and the commercial 
budesonide) was determined according to the 
Comité Européen de Normalisation (CEN) 
methodology (see Figure 1) (18). As discussed 
previously (19), the amount of budesonide was 
determined directly instead of a using fluoride 
tracer. 4 mL of each sample was introduced 
into the nebulizer chamber of the Sidestream 
jet nebulizer (the Respironics, UK). As shown 
in Figure 1, a breathing simulation machine 
(Pari GmbH, Germany) was set at a sinus flow 
of 15 breaths per minute with an inhalation: 
exhalation ratio of 1:1 and a tidal volume of 
500 mL. Two electrostatic filters (Pari GmbH, 
Germany) were used to collect the fractions 
of dose released during the exhalation and 
inhalation phase of the breathing cycle. The 
nebulization process was stopped one minute 
after the occurrence of sputtering (the point at 
which the nebulizer stops continuous work). The 
budesonide deposited on the filters as well as the 
one remained in the chamber and T-piece were 
extracted with methanol/water solution (70:30) 
and quantified by high performance liquid 
chromatography (HPLC) as detailed previously 
(19). Three determinations were performed for 
each preparation.
Aerodynamic diameter
From the CEN methodology for the 
aerodynamic characterization of the emitted 
dose, stages of the Marple 298 x cascade 
impactor represent the cut off values of 50, 
21.3, 14.8, 9.8, 6.0, 3.5, 1.55, 0.93 and 0.52 
µm from top to the bottom, respectively. 
Amounts of budesonide ND and commercial 
suspension were determined in each stage. 
The airflow through the cascade impactor was 
set at a continuous flow of 2 L/min, while a 
further 13 L/min drawn from a second pump 
connected between the cascade impactor and 
the nebulizer (see Figure 2). Accordingly, the 
total airflow across the outlet of the nebulizer 
is 15 L/min. Budesonide deposited onto glass 
filters (Omega speciality instruments, USA) of 
each stage was extracted by methanol-water 
solutions and quantified using HPLC. The 
Copley inhaler testing data analysis software 
(CITDAS, Copley Scientific, UK) was used 
to calculate the mass median aerodynamic 
diameter (MMAD), fine particle fraction 
(FPF) (i.e. the percentage of particles with an 
aerodynamic diameter less than 5 µm), and 
geometric standard deviation (GSD). A student 
t-test was used to examine the differences 
between the studied groups.
Physical stability
In order to check the physical stability 
of budesonide nanodispersion, particle size 
of the prepared budesonide ND, kept in 
glass containers at 4 °C and at 25 °C, was 
monitored. The changes in the particle size 
may be considered as indication of physical 
instabilities.
Results 
Solubility studies
Figure 3 represents the results of solubility 
Figure 1. Schematic diagram of aerosol output system.
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studies of budesonide in solvent (ethanol), 
antisolvent (water) and different ethanol-water 
combinations. Starting with low aqueous 
solubility (0.028 mg/mL), the solubility of 
budesonide was found to gradually increase 
by addition of ethanol until ethanol/water ratio 
of 40:60. Above this point, a marked increase 
in budesonide solubility was observed with 
further addition of ethanol until a mean 
(standard deviation, SD) of 34.00 (0.61) mg/
mL at 90:10, ethanol: water, followed by a 
decrease to a value of 26.84 (0.29) mg/mL in 
pure ethanol.
Microfluidic nanoprecipitation
Budesonide nanodispersions (Z-Ave, 150 
to 350 nm) with narrow size distribution (PDI, 
Figure 2. Schematic diagram aerodynamic particle size measurement.
0.10 to 0.22) were prepared using different 
microreactors under different processing 
conditions.  As the Table 1 shows, the different 
processing conditions studied do not seem to be 
substantially affecting the size/polydispersity. 
Variation in flow rate of antisolvent was found 
to have a major effect on the drug particle 
size. The data also show that relatively smaller 
particles were generated with increasing drug 
concentration. In addition, it was observed 
that smaller particles may be generated using 
microreactors with smaller-sized internal 
diameters and/or with decreasing inlet angle.
Particle size analysis of the tested 
preparations
PCS analysis of the budesonide ND showed 
Figure 3. Solubility of budesonide in different ethanol-water combinations at 25 °C (n=3).
SM Ali H et al. / IJPR (2014), 13 (3): 785-795
790
that the mean particle size was 160 nm and 
PDI was 0.15. Whereas, the mean particle size 
of the marketed suspension was 3802 nm and 
PDI was 0.2. This finding is in agreement with 
previous reports stating that the particle size of 
budesonide of the marketed suspension are 2-3 
µm in diameter (20) or 4400 nm (9). 
Budesonide particles morphology
Micrographs obtained using SEM and TEM, 
as complementary works to PCS, showed 
marked differences between budesonide particles. 
Unprocessed budesonide particles are irregular 
shaped crystals with diameter less than 5 µm 
(Figure 4A). After the nanoprecipitation process, 
budesonide particles appear to be spherical with 
smooth surfaces (Figures 4B and 4C). The observed 
diameter of dried budesonide ND was found 
to be smaller than the hydrodynamic diameter 
obtained by PCS analysis which is reported before 
(21). Budesonide particles from the commercial 
suspension are larger with sizes of 3-4 µm (Figure 
4D). It is worth noticing that the agglomerations 
observed in the EM pictures might be due to the 
drying processes carried before EM.
Aerosolization study
Particle size distribution
Figure 5 displays the deposition pattern 
of budesonide ND and the commercial 
suspension as quantified from different stages 
of cascade impactor. The MMAD value in the 
microsuspension was significantly (p < 0.05) 
larger than MMAD of budesonide ND (see Table 
Figure 4. Morphology of different budesonide particles A. Unprocessed budesonide (SEM, bar = 5 µm), B and C. Dried nanodispersion 
(TEM, bar = 0.5 and 0.2 µm, respectively), D. Dried commercial suspension (SEM, bar = 10 µm).
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2). Furthermore, the fine particle fraction (i.e. 
the fraction less than 5 µm) was significantly 
smaller (p < 0.05) in case of microsuspension 
compared with that of budesonide ND (Table 2). 
These data indicate better performance for the 
nanodispersion.
Aerosol output
The results of the aerosol output studies (see 
Table 3) showed that the nebulisation time for 
budesonide ND is significantly (p < 0.05) shorter 
than that of the microsuspension. 
Overall, the comparative dose delivered to 
lung (estimated by multiplying the FPF and 
the % of dose retained on inhalation filter (20)) 
achieved by budesonide ND is 8.10 % of nominal 
dose compared with 5.68 % for the commercial 
microsuspension.
Physical stability
For budesonide ND stored at room 
Figure 5. Deposition of budesonide (µg) on each stage of the cascade impactor using the CEN 
method for the budesonide ND and the marketed microsuspension (1 mg in 2 mL of budesonide as nominal dose) (n=3).
temperature, peaks of larger particles (5067 
nm) and crystal sediments started to appear 
after 4-5 days of storage. However, samples 
stored at 4 °C, were found to have a particle 
size fluctuating between 200-300 nm over a 
period of 10 days (see Figure 6), indicating a 
more stable preparation. The measured zeta 
potential of budesonide ND was -7.93 and -2.00 
when using water only and water containing 
polysorbate 80 as antisolvent, respectively.
Discussion
Fluid flow in microchannels is laminar. 
Accordingly, the nano-sized particles are 
generated in the interface of the solvent and 
antisolvent through a diffusion procedure. The 
organic solvent containing the drug molecules 
compensates the depletion of budesonide from the 
diffusion layer due to nucleation and/or particle 
growth. This process involves supersaturation, 
                                         Preparation
Parameter Budesonide nanodispersion Budesonide microsuspension
FPF (%) 56.88 (3.37) 38.04 (7.82)
MMAD (μm)  3.91 (0.49) 6.22 (1.09)
 GSD 2.86 (0.26) 2.20 (0.30)
Table 2. The mean (SD) results obtained from cascade impactor for the marketed microsuspension and budesonide nanodispersion 
aerosolized using the Sidestream jet nebulizer (n=3).
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Budesonide
Nanodispersion 
Budesonide
Microsuspension 
Inhalation Filter (percent of the nominal dose) 14.24 (2.51) 14.97 (4.3)
Exhalation Filter (percent of the nominal dose) 14.92 (3.21) 15.27 (4.48)
Chamber (percent of the nominal dose) 69.33 (5.08) 68.36 (8.95)
Connector (percent of the nominal dose) 1.49 (0.33) 1.39 (0.20)
Nebulization time (min) 12.30 (0.37) 14.85 (0.36)
Table 3. The mean (SD) emitted dose of budesonide from the jet nebulizer (n=3).
Figure 6. Change in particle size and polydispersity index (PDI) of budesonide nanodispersion stored at 4 °C (n=1).
formation of drug nuclei, and particle growth. 
The nuclei size start to increase and eventually 
the particles precipitate. Nevertheless, addition 
of surfactants or polymers has been reported to 
control the growth/precipitation rate (5, 22).
Solubility studies
This study employed ethanol as a 
solvent system since it is water-miscible, 
pharmaceutically acceptable and commonly 
used in inhalation products. The solubility 
experiments showed an increase in the solubility 
of budesonide by addition of ethanol to water. 
Nevertheless, the solubility decreases when the 
solvent contains 100% ethanol compared with a 
solvent system of ethanol/water (90:10). Similar 
solubility patterns have been observed for other 
drug molecules including lamotrigine, diazepam, 
and clonazepam in ethanol + water mixtures (23). 
The findings would provide guidance for the 
amounts of budesonide that could be precipitated 
using different ratios of solvent and antisolvent 
in the microfluidic reactors experiments.
Microfluidic nanoprecipitation
The results of the effect of different 
processing conditions on the size/polydispersity 
showed that the effects appear to be complex, 
as discussed previously using artificial neural 
networks (ANNs) (7). The effect of flow 
rate is most probably due to inducing higher 
supersaturation and drug nucleation at higher 
antisolvent flow rates when keeping solvent rate 
constant. This results in reducing the size of 
generated particles, as reported previously (7). 
Higher supersaturation and nucleation, made 
by increasing drug concentration makes the 
particles smaller, as indicated in this work. Also, 
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as a result of better mixing process, smaller 
internal diameters make the particles smaller 
(24). Furthermore, budesonide particle size 
was found to decrease using microreactors with 
reducing inlet angle as reported before (7).  
Aerosolization studies
The results obtained from the PCS showed 
approximately 20-fold decrease in the particle 
size of the budesonide ND compared to 
the corresponding microsuspenison. It is 
already shown that decreasing the size to 
obtain nanoparticles, makes a considerable 
improvement in the rate of drug absorption 
(25). Therefore, a better in-vivo efficacy may be 
expected, provided an improved aerosolization 
performance is observed.
The aerodynamic size studies performed 
in this work, showed a better in-vitro behavior 
in the nanodispersion compared with the 
microsuspension. With the two preparations 
containing nearly equal amounts of surfactant 
and drug, it is hypothesized that the difference in 
budesonide particle size between the commercial 
microsuspension and budesonide ND is the 
primary and dominant factor for the difference in 
drug disposition between the two preparations. 
The smaller drug particles require reduced 
energy to be aerosolized and incorporated in 
aerosol droplets. Thus, smaller aerosol droplets 
are generated from the nebulizer. 
However, considering the details, some ultra 
small aerosol droplets may be observed (see 
filter in Figure 5), indicating a bimodal pattern 
in the size distribution of aerosol droplets. It is 
arguable that during the nebulization, few (or 
a single) nanoparticles get-together to form the 
small and ultra small particles (stage 8 and filter 
in Figure 5, respectively), while larger aerosol 
droplet contain more particles. Such aerosol 
droplets reported in Figure 5 may be exhaled 
before depositing in the respiratory airways (26). 
On the other hand, it is already reported that such 
particles may deposit in the alveolar region of lung 
by diffusion, an advantage to employ the nano-
preparations (27, 28). Undoubtedly, generalizing 
our in-vitro findings will only be possible when 
in-vivo studies are performed too. Especially, 
when considering the fact that similar to many 
other corticosteroids, budesonide reaches the 
receptor by diffusing into cells. Therefore, faster 
dissolution in the airways is preferred which is 
obtained when having nano-sized particles (14).
The aerosol output results showed a slightly 
shorter nebulisation time for the nanodispersion. 
This is advantageous as lengthy treatment times 
may lead to poor compliance of the patient. 
Moreover, analysis of inhalation filters indicated 
that nearly equal amounts of budesonide were 
recovered from the commercial product and 
budesonide ND. Also, the amounts of budesonide 
recovered from exhalation filters and remaining 
in the nebulizer chambers were similar for both 
tested formulations.
In total, an approximately 1.4 fold increase 
in the dose delivered to the lung may be 
estimated for the nanodispersion compared with 
the commercial preparation. This is another 
indicator of better performance of nebulized 
nanodispersion in-vitro.
Physical stability
The bottom-up prepared nano-budesonide 
dispersion was prepared using polysorbate 
80, as a stabilizer, similar to the commercial 
microsuspension. The stabilizing effect of 
polysorbate 80 comes from its ability to be 
adsorbed and cover the generated particle 
surfaces (sterical effect). The changes in the size 
observed in this work, might be from dissolution 
of drug nanoparticles (in case of decreasing 
particle size) or particle growth due to Ostwald 
ripening and/or occasionally agglomeration 
of the particles (29). The difference in zeta 
potential values may arise from adsorption of the 
non-ionic stabilizer on drug particles resulting in 
increase in the thickness of the diffuse double 
layer and hence a lower zeta potential (30).
Conclusion
The capability of bottom-up prepared 
budesonide nanodispersions as alternatives to 
the corresponding microsuspension formulations 
for delivery to the lungs using nebulizers has 
been demonstrated. The overall results showed 
similar patterns for the in-vitro aerosol output 
studies. However, the aerodynamic droplet size 
and the nebulization time were improved when 
using the nanodispersion compared with the 
SM Ali H et al. / IJPR (2014), 13 (3): 785-795
794
Filippos Kesisoglou, Santipharp Panmai and Yunhui 
Wu. Nanosizing-oral formulation development and 
biopharmaceutical evaluation. Adv. Drug. Deliv. Rev. 
(2007) 59: 631-644.
Dandagi P, S Kerur V, Mastiholimath A and Gadad 
A. Kulkarni. Polymeric ocular nanosuspension for 
controlled release of acyclovir: in-vitro release and 
ocular distribution. Iran J. Parm. Res. (2010) 8: 79-86.
Hecq J, M Deleers, D Fanara, H Vranckx and K Amighi. 
Preparation and characterization of nanocrystals 
for solubility and dissolution rate enhancement of 
nifedipine. Int. J. Pharm. (2005) 299: 167-177.
Weigl BH, RL Bardell and CR Cabrera. Lab-on-a-chip 
for drug development. Adv. Drug Deliv. Rev. (2003) 55: 
349-377.
Weibel DB and GM Whitesides. Applications of 
microfluidics in chemical biology. Curr. Opin. Chem. 
Biol. (2006) 10: 584-591.
Aghajani M, AR Shahverdi, SM Rezayat, MA 
Amini and A Amani. Preparation and optimization 
of acetaminophen nanosuspension through 
nanoprecipitation using microfluidic devices- an 
artificial neural networks study. Pharm. Dev. Technol. 
(2013): 18: 609-618.
Ali HSM, N Blagden, P York, A Amani and T Brook. 
Artificial neural networks modelling the prednisolone 
nanoprecipitation in microfluidic reactors. Eur. J. 
Pharm. Sci. (2009) 37: 514-522.
Zhao H, JX Wang, QA Wang, JF Chen and J Yun. 
Controlled liquid antisolvent precipitation of 
hydrophobic pharmaceutical nanoparticles in a 
microchannel reactor. Ind. Eng. Chem. Res. (2007). 
46: 8229-8235.
Kraft WK, B Steiger, D Beussink, JN Quiring, N 
Fitzgerald, HE Greenberg and SA Waldman. The 
pharmacokinetics of nebulized nanocrystal budesonide 
suspension in healthy volunteers. J. Clin. Pharmacol. 
(2004) 44: 67.
Luangvala MM, MC Castillo and AP Bosco. A novel 
submicron formulation of nebulized budesonide 
significantly decreases the nebulization time from a 
variety of commercially available jet nebulizers. J. 
Allergy Clin. Immunol. (2009) 123: 81.
Amani A, MA Amini, HSM Ali and P York. Alternatives 
to conventional suspensions for pulmonary drug 
delivery by nebulisers: A review. J. Pharm. Sci. (2011) 
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
microsuspension indicating improved in-vitro 
performance for this formulation. 
Acknowledgments
Authors would like to acknowledge the 
Egyptian Government (Ministry of High 
Education) for funding.
References
100: 4563-4570.
Shrewsbury SB, AP Bosco and PS Uster. 
Pharmacokinetics of a novel submicron budesonide 
dispersion for nebulized delivery in asthma. Int. J. 
Pharm. (2009) 365: 12-17.
Rogueda PGA and D Traini. The nanoscale in 
pulmonary delivery. Part 1: deposition, fate, toxicology 
and effects. Expert. Opin. Drug Deliv. (2007) 4: 595-
606.
Jacobs C and RH Muller. Production and 
characterization of a budesonide nanosuspension for 
pulmonary administration. Pharm. Res. (2002) 19: 
189-194.
Bosco AP and PS Uster. A novel submicron suspension 
formulation of nebulized budesonide significantly 
improves the fine particle dose and ultra-fine particle 
dose. J. Aerosol. Med. (2007) 20: 25.
Muller RH and CM Keck. Challenges and solutions 
for the delivery of biotech drugs-a review of drug 
nanocrystal technology and lipid nanoparticles. J. 
Biotechnol. (2004) 113: 151-170.
Rezaei Mokarram A, A Kebriaee zadeh, M Keshavarz, 
A Ahmadi and B Mohtat. Preparation and in-vitro 
evaluation of indomethacin nanoparticles. DARU 
(2010) 18: 185-192.
Boe J, JH Dennis, BR O’Driscoll, TT Bauer, M Carone, 
B Dautzenberg, P Diot, K Heslop and L Lannefors. 
European Respiratory Society Guidelines on the use of 
nebulizers. Eur. Respir. J. (2001) 18: 228-242.
Amani A, P York, H Chrystyn and BJ Clark. Evaluation 
of a nanoemulsion-based formulation for respiratory 
delivery of budesonide by nebulizers. AAPS Pharm. 
Sci. Tech. (2010) 11: 1147-1151.
Vaghi A, E Berg, S Liljedahl and JO Svensson. In-
vitro comparison of nebulised budesonide (Pulmicort 
Respules®) and beclomethasone dipropionate (Clenil® 
per Aerosol). Pulm. Pharmacol. Therapeutics (2005) 
18: 151-153.
Aboofazeli R, DJ Barlow and MJ Lawrence. 
Particle size analysis of concentrated phospholipid 
microemulsions: II. Photon correlation spectroscopy. 
AAPS J. (2000) 2: 1-10.
Nan Z, G Lijun, W Tao and Dongqin. Evaluation 
of Carbamazepine (CBZ) Supersaturatable Self-
Microemulsifying (S-SMEDDS) Formulation In-vitro 
and In-vivo. Iran. J. Pharm. Res. (2012) 11: 257.
Shayanfar A, MAA Fakhree, WE Acree and A Jouyban. 
Solubility of Lamotrigine, Diazepam, and Clonazepam 
in Ethanol + Water Mixtures at 298.15 K. J. Chem. 
Eng. Data (2008) 54: 1107-1109.
Aoki N and K Mae. Effects of channel geometry on 
mixing performance of micromixers using collision of 
fluid segments. Chem. Eng. J. (2006) 118: 189-197.
Lakshmi P and KG Ashwini. Nanosuspension 
technology: A review. Int. J. Pharm. Sci. (2010) 2: 
35-40.
Bai F, X Yang, R Li, B Huang and W Huang. 
Monodisperse hydrophilic polymer microspheres 
having carboxylic acid groups prepared by distillation 
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
Nanodispersion of budesonide for nebulization
795
This article is available online at http://www.ijpr.ir
precipitation polymerization. Polymer. (2006) 47: 
5775-5784.
Byron PR. Prediction of drug residence times in 
regions of the human respiratory tract following 
aerosol inhalation. J. Pharm. Sci. (1986) 75: 433-438.
Sung JC, BL Pulliam and DA Edwards. Nanoparticles 
for drug delivery to the lungs. Trends Biotechnol. 
(2007) 25: 563-570.
Moschwitzer J, G Achleitner, H Pomper and RH 
Moller. Development of an intravenously injectable 
(27)
(28)
(29)
chemically stable aqueous omeprazole formulation 
using nanosuspension technology. Eur. J. Pharm. 
Biopharm. (2004) 58: 615-619.
Verma S, R Gokhale and DJ Burgess. A comparative 
study of top-down and bottom-up approaches for the 
preparation of micro/nanosuspensions. Int. J. Pharm. 
(2009) 380: 216-222.
(30)
or
 http:// ijpr.sbmu.ac.ir
Search full text articles? 
Visit http://www.ijpr.ir
Journal alert and more ...
Visit http://www.ijpr.ir
or
 http:// ijpr.sbmu.ac.ir
